PTX_V1: THERAPEUTIC VACCINE FOR MUCOSAL HPV AND HPV INDUCED CANCERS

Infection with the human papilloma virus (HPV) is the most common sexually transmitted disease and leads to genital warts, pre-cancerous lesions and cancer. HPV is responsible for around 90% of cervical cancers. Current treatment is defined by prophylactic vaccines that have no impact for the 630 million already infected with the HPV globally. There is an unmet need to create a therapeutic that can clear the HPV infection for these patients.

pHion Therapeutics has developed a RALA-mRNA therapeutic vaccine (PTX_V1) that can deliver to antigen producing cells and induce a potent therapeutic CD8+ response.

​

Phase I/IIA clinical trials are planned to commence in 2023.

​

PTX_V2: CUTANEOUS HPV VACCINE

Active HPV infections exist in 42.5% of adults, aged 16-69, with 22.8% of all adults currently with high risk genital strains associated with cervical and vaginal cancers.  For, cutaneous HPV, the prevalence is estimated to be ~50% of healthy individuals. These epidemiological numbers equate to an incidence of over 80 million individuals in the EU and US for which a prophylactic, mucosal HPV vaccine is ineffective.  Further patient need exists with ~ 200 million individuals possessing cutaneous HPV infections that would benefit from a therapeutic vaccination.

pHion Therapeutics are developing a RALA-mRNA therapeutic vaccine (PTX_V2) that targets non-basal cell carcinoma for the therapeutic treatment of  CUTANEOUS HPV.

​

PTX_V3: PROSTATE CANCER VACCINE

pHion Therapeutics are currently engaged in pre-clinical development of a RALA-mRNA therapeutic vaccine for  PROSTATE CANCER (PTX_V3).

​

PTX_V4: COVID-19 VACCINE

Vaccine approvals for SARS-CoV-2 have transformed the mRNA landscape, however, the rate at which the S-Glycoprotein antigen mutates is cause for concern, as is the reliance on a single antigen vaccine.

pHion Therapeutics are developing a next generation prophylactic vaccine against SARS-CoV-2 (PTX_V4). The vaccine is designed to encode for multiple COVID-19 variants and can be stored and transported at room temperature.

​

PTX_V5: OVARIAN CANCER VACCINE

​

pHion Therapeutics are developing a vaccine for  Ovarian Cancer (PTX_V5).

​

PTX_C1: ADVANCED CHEMOTHERAPY FOR PANCREATIC CANCER

There were 460,000 new pancreatic cancer cases diagnosed worldwide in 2020. Prognosis in in these cases is very poor with survival rates of 25% in year 1, and 5% in 5+ years (Cancer Reearch UK).

Gemcitabine is the most widely indicated of the nucleoside chemotherapies, prescribed as a first line of therapy for pancreatic cancer and is used extensively in other cancer treatments, including breast cancer, ovarian cancer and  non-small cell lung cancer (NSCLC).  However, gemcitabine rapidly develops drug resistance that yields a clinical response rate as low as 6%.

pHion are validating and developing a RALA-gemcitabine-triphosphate(dFdCTP) nanoparticle (PTX_C1) for the treatment of pancreatic cancer.

​

pHion is capable of delivering the active triphosphate metabolite which ensures an absolute dose, and bypasses typical intracellular resistance mechanisms.

​